Specialty
Dermatology clinical trials
Trials in psoriasis, atopic dermatitis, acne, vitiligo, hidradenitis suppurativa, alopecia and other skin conditions.
About dermatology research
Dermatology studies are led by biologic and oral targeted treatments for inflammatory skin disease, with further studies of topical treatments, hair loss, pigment disorders and chronic itch.
Research areas
Open trials in each area. Counts come from the latest copy of the registry.
Recently updated open trials
Studies looking for volunteers, most recently updated by their sponsors first.
Non-Segmental Vitiligo (NSV)
A Study of EB06 Versus Placebo in Adults With Moderate to Severe Non-segmental Vitiligo
The purpose of this study is to evaluate the safety and efficacy of EB06 intravenous infusion (loading dose of 20mg/kg followed by a maintenance dose of 10mg/kg) compared with placebo in adults with moderate to severe…
- Trial name
- NCT07889492
- Testing
- EB06
- Where
- 4 sites in Canada
- Volunteers
- 80 people
- Sponsor
- Edesa Biotech Inc.
Atopic Dermatitis (AD)
Phase II Clinical Study to Evaluate the Efficacy and Safety of LT-002-158 Tablets in Adult Patients With Moderate-to-Severe Atopic Dermatitis
The goal of this clinical trial is to learn if drug LT-002-158 works to treat moderate-to-severe atopic dermatitis in adults. It will also learn about the safety of drug LT-002-158.
- Trial name
- NCT07895615
- Testing
- LT-002-158
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.
Atopic Dermatitis, Eczema
A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
The main purpose of this study is to assess the long-term safety and efficacy of lebrikizumab in participants 6 Months to <18 years of age with moderate-to-severe atopic dermatitis.
- Trial name
- ADorable-2 (NCT05735483)
- Testing
- Lebrikizumab
- Where
- 94 sites in United States, Argentina and 11 more
- Volunteers
- 338 people
- Sponsor
- Eli Lilly and Company
Eczema, Dermatitis
Effects of Treatments on Atopic Dermatitis
Background: Atopic dermatitis, or eczema, is a chronic skin disorder. Patients sometimes have infections with S. aureus bacteria.
- Conditions
- Eczema, Dermatitis, Skin Diseases, Genetic, Dermatitis, Atopic
- Trial name
- NCT01631617
- Testing
- Trimethoprim/sulfamethoxazole (TMP/SMZ), Cephalexin, Doxycycline
- Where
- United States
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Relieves Vaginal Dryness / Improves Self-Lubrication, Improves Strength & Elasticity of Vagina (Aka Collagen and Elastin)
A Clinical Trial to Evaluate the Effects of the NeuEve Dryness Treatment Kit on Vaginal Health, Comfort, and Quality of Life in Postmenopausal Women
This is a decentralized, single-group, open-label clinical trial evaluating a 12-week regimen of the NeuEve Dryness Treatment Kit (comprising Feminine Moisture Support oral softgels, Bone Support oral capsules, NeuEve Salve…
- Conditions
- Relieves Vaginal Dryness / Improves Self-Lubrication, Improves Strength & Elasticity of Vagina (Aka Collagen and Elastin), Improves Vaginal Wall Thickness, Reduces Pain During Sex
- Trial name
- NCT07893795
- Testing
- Intervention
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- NeuEve
Alopecia Areata
A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata
The purpose of this clinical study is to learn about the safety and effects of the study medicine (called ritlecitinib) for the potential treatment of moderate alopecia areata (AA).
- Trial name
- NCT07733765
- Testing
- Ritlecitinib 100 mg, Ritlecitinib 50 mg
- Where
- 38 sites in United States, Canada and 3 more
- Volunteers
- 336 people
- Sponsor
- Pfizer
Chronic Spontaneous Urticaria
A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.
The purpose of the study is to learn about the safety and effects of the study medicine (called ritlecitinib) for the treatment of chronic spontaneous urticaria (CSU) that is not effectively treated by antihistamines which are…
- Trial name
- NCT07219615
- Testing
- Ritlecitinib 50 mg, Ritlecitinib 100 mg
- Where
- 77 sites in United States, Bulgaria and 8 more
- Volunteers
- 200 people
- Sponsor
- Pfizer
Hyper IgE Syndrome From STAT3 Mutation, Job s Syndrome
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
Background: Autosomal dominant hyper-IgE syndrome (HIES), also called Job syndrome, is a genetic disorder that affects the immune system.
- Conditions
- Hyper IgE Syndrome From STAT3 Mutation, Job s Syndrome, HIES, Lupus
- Trial name
- NCT07262983
- Testing
- baricitinib
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Narrow the search
Conditions in dermatology
Conditions with their own page on AzTrials, with the number of registered studies.
Questions about dermatology trials
Which trials are counted as dermatology?
Studies whose conditions, or the medical subject headings the registry adds to them, mention any of these terms: psoriasis, atopic dermatitis, eczema, acne, vitiligo, hidradenitis, alopecia, urticaria, rosacea, pruritus. A study can belong to more than one specialty, and the grouping is AzTrials', not the sponsor's.
Are all of these trials recruiting?
No. The lists on this page show studies open to volunteers (recruiting, not yet recruiting or enrolling by invitation), as the sponsor last reported. The full search also includes completed and stopped studies, some with posted results.
How can I refer a patient to one of these trials?
Open the trial and use the contacts and sites it lists; the For doctors view of each trial collects them with the key eligibility criteria. AzTrials does not enrol participants or take referrals.